Latest Immunotherapy Treatments
The ONCOS-102 immunotherapy vaccine was given the Fast-Track Designation, which will speed up regulatory approval. The vaccine is used to treat mesothelioma and other cancers. Targovax, which developed the treatment, is taking this as an endorsement from the FDA. Targovax is a small biotech company that mainly works with oncolytic viruses. The company believes that…
A group of drugs called statins used for controlling cholesterol are showing that they can help mesothelioma patients taking PD-1 inhibitors survive longer. Researchers in Italy and the Netherlands found this information in an international study of 250 patients. The patients studied either had pleural mesothelioma or non-small cell lung cancer. The researchers found that…
The ONCOS-102 immunotherapy vaccine is still showing promising results. Information from November shows when patients take the treatment with chemotherapy, it helped patients survive a minimum of 18.2 months. The median overall survival was four months better in the experimental group compared to the control group. Targovax, the maker of the treatment, believes that it…
A new clinical trial at the Memorial Sloan Kettering Cancer Center is recruiting patients for a pleural mesothelioma study. The treatment involves T-cell therapy and is a very promising treatment for mesothelioma sufferers. The reason the study is being done is ATA2271, which is known as CAR T-cell therapy, was recently approved by the Food…
A new treatment has been approved for mesothelioma by the Food and Drug Administration (FDA). The treatment uses a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), which are immunotherapy drugs created by Bristol-Myers Squibb. It is the first new drug combination approved for mesothelioma in 16 years. The most recent approved treatment involved Tumor Treating…
Mesothelioma is a cancer with a bad prognosis that is primarily caused by asbestos exposure. There is no cure for mesothelioma, so people diagnosed with the disease do not have a great chance of living long past their diagnoses. Clinical trials are people’s best chance of finding a better treatment or even a cure, so…
A new mesothelioma clinical trial is taking place in Oslo, Norway. The trial is looking at the UV1 cancer vaccine alongside immunotherapy. The vaccine is a peptide-based drug that activates a T-cell response, allowing the immunotherapy drugs to work better. This will be the first time that UV1 is being tested on mesothelioma, but it…
A clinical trial being tested on lung cancer could potentially be a good treatment for people with mesothelioma. The combination of Keytruda and Tumor Treating Fields is being tested for non-small cell lung cancer. Keytruda is an immune checkpoint inhibitor that allows the immune system to find cancer cells hiding within the PD-1 pathway. It…
The combination of Yervoy and Opdivo was tested on mesothelioma and the overall survival was promising. The overall survival was 18.1 months versus 14.1 months for patients receiving just chemotherapy. This is the first time that a phase III trial had an improved survival with an immunotherapy combination in a first line setting. Doctors doing…
Genetically modified T cells are a promising treatment for those suffering from mesothelioma. There is only data from five patients, but the results so far look good. The Phase I part of the study is looking at the safety and efficacy of the treatment and is finding out what dosage is best for treating people.…
